Brief: Poxel Presents Complete PXL770 Phase 1 Results

Poxel SA

04/10/2018 07:05

Oct 4 (Reuters) - POXEL SA  POXEL.PA :
    * POXEL PRESENTS COMPLETE PXL770 PHASE 1 RESULTS, CARDIAC
SAFETY
PROFILE AND PRECLINICAL EFFICACY DATA IN NASH AT AMPK - FROM
MECHANISMS TO NEW THERAPIES SCIENTIFIC CONGRESS
    * PHASE 1 CLINICAL PROGRAM FOR PXL770 WAS OBSERVED TO HAVE A
FAVORABLE PHARMACOKINETIC, TOLERABILITY AND SAFETY PROFILE
    * PXL770 WAS OBSERVED TO HAVE A FAVORABLE CARDIAC SAFETY
PROFILE
IN BOTH HEALTHY SUBJECTS AND IN ANIMAL MODELS
    * PXL770 WAS OBSERVED TO SHOW EFFICACY IN A DIET-INDUCED
OBESE-NASH MICE MODEL

Source text for Eikon:  urn:newsml:reuters.com:*:nBwPJ0n1a
Further company coverage:  POXEL.PA 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 09 20;))